Finite-Lived Intangible Assets by Major Class [Axis]
Trade Name [Member]
State Pharmacy Licenses [Member]
Customer Relationships [Member]
Range [Axis]
Minimum [Member]
Non-Competition Clause [Member]
Maximum [Member]
Trademarks [Member]
Patents [Member]
Class of Warrant or Right [Axis]
Warrant [Member]
Type of Arrangement and Non-arrangement Transactions [Axis]
Sales Agreement [Member]
Legal Entity [Axis]
Cantor Fitzgerald & Co [Member]
Award Type [Axis]
Restricted Stock Units [Member]
Klarity License Agreement [Member]
Title of Individual [Axis]
Richard L. Lindstrom, M.D [Member]
Licenses [Member]
Sales and Marketing Agreements [Member]
Product and Service [Axis]
Product Sales, Net [Member]
License Revenues [Member]
Eton Pharmaceuticals, Inc. [Member]
Andrew R. Boll [Member]
John P. Saharek [Member]
Stock Option Plan [Member]
Unvested RSUs [Member]
Consultants, Employees and Directors [Member]
Options Granted to Employees [Member]
Exercise Price Range [Axis]
Range One [Member]
Range Two [Member]
Range Three [Member]
Range Four [Member]
Range Five [Member]
Related Party [Axis]
Lender Warrants [Member]
Settlement Warrants [Member]
PIPE Investor and Placement Agent Warrants [Member]
Lender Warrants One [Member]
Surface Pharmaceuticals [Member]
Eton Pharmaceuticals [Member]
Non Employee Directors [Member]
Debt Instrument [Axis]
Note Payable [Member]
Employees and Consultants [Member]
Antidilutive Securities [Axis]
Deferred Acquisition Obligations, Convertible Note Payable, Stock Options, Unvested RSUs and Warrants [Member]
Class of Stock [Axis]
Surface Series A Stock [Member]
Surface Pharmaceuticals Inc [Member]
Surface License Agreements [Member]
Management Services Agreement [Member]
Dr. Lindstrom [Member]
Equity Components [Axis]
Common Stock Warrants [Member]
Common Stock Warrant One [Member]
Plan Name [Axis]
2017 Incentive Stock and Awards Plan [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Billing and Collection Agreement [Member]
Third Party [Member]
Option Indexed to Issuer's Equity, Type [Axis]
Stock Option [Member]
Eton License Agreements [Member]
Management Services Agreement [Member]
Asset Purchase Agreement [Member]
Pharmacy Solutions Central, LLC [Member]
Scenario [Axis]
December 31, 2017 [Member]
Stock Purchase Agreement [Member]
Livernois [Member]
Imprimis TX [Member]
Loan Agreement [Member]
Life Sciences Alternative Funding LLC [Member]
SWK Loan Agreement [Member]
LSAF Loan [Member]
Variable Rate [Axis]
London Inter-Bank Offered Rate [Member]
SWK Warrants [Member]
Measurement Input Type [Axis]
Expected Term [Member]
Dividend Rate [Member]
Risk Free Interest Rate [Member]
Notes Payable [Member]
Lease Agreement [Member]
Amended Lease Agreement [Member]
Commercial Lease Agreement [Member]
February 2019 [Member]
Initial Payment [Member]
License Agreement [Member]
Second Payment [Member]
Final Payment [Member]
Settlement Agreement [Member]
Concentration Risk Type [Axis]
Three Main Suppliers [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Cashless Warrants Exercise [Member]
May Asset Purchase Agreement [Member]
Elle Pharmaceutical, LLC [Member]
Elle Royalty Agreement [Member]
Mayfield Pharmaceutical, LLC [Member]
May Asset Purchase And Elle Royalty Agreement [Member]
Pharmaceutical Compounding [Member]
Pharmaceutical Drug Development [Member]
Securities Purchase Agreements [Member]
Two Accredited Investors [Member]
Restricted Stock [Member]
Employees [Member]
Income Statement Location [Axis]
Selling and Marketing [Member]
General and Administrative [Member]
Directors [Member]
Consultants [Member]
Volatility [Member]
Amended and Restated Certificate of Incorporation [Member]
Previously Authorized Shares [Member]
Stock Option Plan [Member]
Income Tax Authority [Axis]
Tax Reform [Member]
Corporate [Member]
Research and Development Expense [Member]
Sale of Stock [Axis]
IPO [Member]
Document And Entity Information
Entity Registrant Name
Entity Central Index Key
Document Type
Document Period End Date
Amendment Flag
Current Fiscal Year End Date
Entity a Well-known Seasoned Issuer
Entity a Voluntary Filer
Entity's Reporting Status Current
Entity Filer Category
Entity Small Business Flag
Entity Emerging Growth Company
Entity Ex Transition Period
Entity Shell Company
Entity Public Float
Entity Common Stock, Shares Outstanding
Trading Symbol
Document Fiscal Period Focus
Document Fiscal Year Focus
Statement [Table]
Statement [Line Items]
ASSETS
Current assets
Cash and cash equivalents, including restricted cash of $200
Investment in Eton Pharmaceuticals
Accounts receivable, net
Inventories
Prepaid expenses and other current assets
Note receivable, current portion
Total current assets
Property, plant and equipment, net
Intangible assets, net
Investment
Note receivable, less current portion
Goodwill
TOTAL ASSETS
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable and accrued expenses
Accrued payroll and related liabilities
Deferred revenue and customer deposits
Current portion of deferred acquisition obligation and accrued interest
Current portion of note payable, net of unamortized debt discount
Current portion of capital lease obligations, net of unamortized discount
Total current liabilities
Capital lease obligations, net of current portion and unamortized discount
Accrued expenses, net of current portion
Note payable, net of current portion and unamortized debt discount
TOTAL LIABILITIES
STOCKHOLDERS' EQUITY
Preferred stock, $0.001 par value, 5,000,000 shares authorized, and no shares issued and outstanding at December 31, 2018 and 2017
Common stock, $0.001 par value, 50,000,000 and 90,000,000 shares authorized, 24,339,610 and 20,623,129 shares issued and outstanding
Additional paid-in capital
Accumulated deficit
TOTAL STOCKHOLDERS' EQUITY
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
Statement of Financial Position [Abstract]
Restricted cash
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Revenues:
Total revenues
Cost of sales
Gross profit
Operating expenses:
Selling, general and administrative
Research and development
Total operating expenses
Loss from operations
Other income (expense):
Interest expense, net
Investment gain
Loss on sale of assets
Other income (expense), net
Total other income (expense), net
Income (loss) before income taxes
Income tax benefit, net
Net income (loss)
Basic net income (loss) per share of common stock
Diluted net income (loss) per share of common stock
Weighted average number of shares of common stock outstanding, basic
Weighted average number of shares of common stock diluted
Balance
Balance, shares
Exercise of warrants
Exercise of warrants, shares
Registered direct offering sale of stock, net of offering costs
Registered direct offering sale of stock, net of offering costs, shares
Sale of stock, net of costs (ATM)
Sale of stock, net of costs (ATM), shares
Stock-based payment for services provided
Stock-based payment for services provided, shares
Relative fair value of warrants to purchase common stock issued in connection with note payable
Stock-based compensation expense
Vesting of RSUs, net of tax withholding
Vesting of RSUs, net of tax withholding, shares
Net income (loss)
Balance
Balance, shares
CASH FLOWS FROM OPERATING ACTIVITIES
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation and amortization of property, plant and equipment
Amortization of intangible assets
Deferred income taxes
Amortization of debt issuance costs and discount
Debt extinguishment
Investment gain
Loss on sale and disposal of assets and write down of assets and note receivable
Stock-based payment for services provided
Stock-based compensation
Changes in assets and liabilities:
Accounts receivable
Inventories
Prepaid expenses and other current assets
Accounts payable and accrued expenses
Accrued payroll and related liabilities
Deferred revenue and customer deposits
NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES
CASH FLOWS FROM INVESTING ACTIVITIES
Repayment of note receivable
Proceeds on sale of assets
Investment in patent and trademark assets
Purchase of Klarity license
Purchases of property, plant and equipment
NET CASH USED IN INVESTING ACTIVITIES
CASH FLOWS FROM FINANCING ACTIVITIES
Payments on capital lease obligations
Net proceeds from public equity offering
Payments on Park deferred acquisition obligation
Proceeds from SWK debt, net of costs
Principal payments on LSAF note payable
Net proceeds from ATM sales of common stock
Net proceeds from exercises of warrants and stock options, net of taxes remitted for RSU's
NET CASH PROVIDED BY FINANCING ACTIVITIES
NET CHANGE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, end of period
RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH
Cash and cash equivalents
Restricted cash
CASH, CASH EQUIVALENTS AND RESTRICTED CASH AT END OF PERIOD
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes
Cash paid for interest
SUPPLEMENTAL DISCLOSURES OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Final fee on note payable recorded as debt discount and included in accrued expenses
Estimated relative fair value of warrants issued in connection with note payable
Note receivable in connection with sale of assets
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization
Accounting Policies [Abstract]
Summary of Significant Accounting Policies
Revenue from Contract with Customer [Abstract]
Revenues
Investments, Debt and Equity Securities [Abstract]
Investment in Eton Pharmaceuticals, Inc. and Agreements - Related Party Transactions
Investment in Surface Pharmaceuticals Inc. and Agreements - Related Party Transactions
Cash and Cash Equivalents [Abstract]
Restricted Cash
Inventory Disclosure [Abstract]
Inventories
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid Expenses and Other Current Assets
Asset Sales And Note Receivable
Asset Sales and Note Receivable
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets and Goodwill
Payables and Accruals [Abstract]
Accounts Payable and Accrued Expenses
Debt Disclosure [Abstract]
Debt
Leases [Abstract]
Capital Lease Obligation
Equity [Abstract]
Stockholders' Equity and Stock-Based Compensation
Income Tax Disclosure [Abstract]
Income Taxes
Retirement Benefits [Abstract]
Employee Savings Plan
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies
Segment Reporting [Abstract]
Segment Information and Concentrations
Subsequent Events [Abstract]
Subsequent Events
Basis of Presentation
Use of Estimates
Liquidity
Revenue Recognition and Deferred Revenue
Cost of Sales
Research and Development
Debt Issuance Costs and Debt Discount
Intellectual Property
Income Taxes
Cash and Cash Equivalents
Concentrations of Credit Risk
Investment in Eton Pharmaceuticals, Inc.
Accounts Receivable
Inventories
Investment in Surface Pharmaceuticals, Inc.
Property, Plant and Equipment
Business Combinations
Goodwill and Intangible Assets
Impairment of Long-Lived Assets
Third Party Billing and Collection Agreements
Deferred Rent
Fair Value Measurements
Stock-Based Compensation
Basic and Diluted Net Income (Loss) Per Common Share
Reclassification
Recently Adopted Accounting Pronouncements
Recently Issued Accounting Pronouncements
Schedule of Basic Earnings Per Common Share
Schedule of Diluted Common Equivalent Shares
Schedule of Diluted Earnings Per Common Share
Schedule of Disaggregated Revenue
Schedule of Condensed Income Statement
Schedule of Condensed Balance Sheet
Schedule of Inventories
Schedule of Prepaid Expenses and Other Current Assets
Schedule of Assets Sales and Note Receivable
Schedule of Property, Plant and Equipment
Schedule of Intangible Assets
Schedule of Amortization Expenses for Intangible Assets
Schedule of Estimated Future Amortization Expense
Schedule of Accounts Payable and Accrued Expenses
Summary of Notes Payable
Summary of Future Minimum Payments
Schedule of Future Payment Under Capital Lease
Schedule of Stock Option Plan Activity
Schedule of Fair Value Assumptions
Schedule of Shares Outstanding and Exercisable
Schedule of Restricted Stock Units Activity
Schedule of Stock Based Compensation Granted to Employees Directors Consultants
Schedule of Warrants Activity
Schedule of Warrants Outstanding and Warrants Exercisable
Schedule of Provision for Income Taxes
Schedule of Income Tax Reconciliation
Schedule of Deferred Tax Assets and Liabilities
Schedule of Change in Unrecognized Tax Benefits
Schedule of Future Payments Under Leases
Schedule of Operating Segment
Loss from operations
Net cash used in operating activities
Cash resources and restricted investments, marketable securities
FDIC insured amount
Gain on deconsolidation amount
Investment gain loss
Number of shares issued
Stock issed price per shares
Stock issed during period value
Ownership percentage
Share purchase price
Gain on investment
Loss on investment
Fair market value of investments
Accounts receivable, net of allowance for doubtful accounts
Proceeds from issuance of preferred stock
Number of shares owned
Property and equipment estimated useful life
Intangible assets estimated useful life
Percentage of billing and collection amount
Billing and collection management expense
Due to related party
Antidilutive securities
Number of shares vested during the period
Right of use asset
Lease liability
Numerator - net income (loss)
Denominator - weighted average number of shares outstanding, basic
Net loss per share, basic
Dilutive common equivalent shares
Weighted average number of shares outstanding, basic
Dilutive common equivalents
Denominator - number of shares used for diluted earnings per share computation
Net income (loss) per share, diluted
Total Revenues
Royalty payment percentage on net sales
Royalty payment percentage on net sales patent claims not issued
Payment on issuances of patent
Proceeds from sale of equity securities
Monthly payment
Amount paid for services
Carry value of investments
Royalty payment description
Proceeds from the sale of equity securities
Administrative expenses
Reimbursable expenses due
Revenues, net
Net loss
Current assets
Non current assets
Total assets
Total liabilities
Total stockholders' equity
Total liabilities and stockholders' equity
Raw materials
Work in progress
Finished goods
Total inventories
Prepaid insurance
Other prepaid expenses
Receivable due from Surface
Deposits and other current assets
Total prepaid expenses and other current assets
Total purchase price
Payment to closing cash amount
Debt interest rate
Debt monthly payment
Debt annual principal payment
Note due amount
Loss on sale of assets
Loss from sale of equipment
Loss on equipment
Sale of stock percentage
Payment of consideration amount
Lease obligation
Asset Sales And Note Receivable - Schedule Of Assets Sales And Note Receivable
Inventories
Furniture and equipment
Asset held for sale
Loss on asset sale
Assets sold
Computer software and hardware
Furniture and equipment
Lab and pharmacy equipment
Leasehold improvements
Property, plant and equipment, gross
Accumulated depreciation and amortization
Property, plant and equipment, Net
Amortization periods (in years)
Amortization periods description
Cost
Accumulated amortization
Impairment
Net Carrying value
2019
2020
2021
2022
Thereafter
Intangible assets
Accounts payable
Deferred rent
Accrued interest
Accrued exit fee for note payable
Total accounts payable and accrued expenses
Less: Current portion
Non-current total accrued expenses
Principal amount of loan
Loan bear interest
Loans bear interest rate description
Percentage of loan agreement final fee
Percentage of loan agreement prepayment fee
Loan due date
Warrant to purchase of common stock
Debt principal amount
Loan agreement term
Loss on extinguishment
Repayment of debt
Debt due date description
Incurred expense debt
Liability of final fee included in accrued expenses
Fair value warrant adjustments
Warrant exercise price per share
Warrant term
Fair value assumptions, measurement input, per share
Fair value assumptions, measurement input, term
Fair value assumptions, measurement input, percentages
Amortization of debt discount
SWK note
Less: Discount on notes
Less: Current portion
Long-term portion
2019
2020
2021
2022
Total minimum payments
Less: amount representing interest
Notes payable, gross
Less: unamortized discount
Less: current portion, net of unamortized discount
Property and equipment purchase price
Lease monthly payments
Lease future payment
Lease incurred expenses
Capital lease future minimum payments percentage
Debt discount amortization
Capital leases of equipment
Capital leases of accumulated depreciation
2019
Total minimum lease payments
Less: amount representing interest payments
Present value of future minimum lease payment
Present value of future net minimum lease payments
Less: current portion, net of unamortized discount
Capital lease obligation net of current portion and unamortized discount
Price per share
Net proceeds of registered offering
Gross proceeds, percentage
Number of shares issued investor relations related services
Number of shares issued investor relations related services, value
Number of common stock issued for warrant exercises
Proceeds from issuance of warrant
Warrants exercise price
Cash commission, percentage
Number of shares sold under the agreement
Proceeds from sale of common stock approximately
Sales commission and offering expenses
Shares issued of restricted common stock, shares
Accrued royalty expense
Fair value of restricted common stock issued
Number of warrants exercised
Maximum number of common stock issuance under the plan
Number of shares available for sales
Closing price of common stock price per share
Stock options granted with exercise price contractual terms
Stock options granted vesting terms
Forfeiture factor, percentage
Unrecognized compensation expense related to unvested stock options granted under the plan
Expense expected to recognize over the weighted-average remaining vesting period
Number of shares, Outstanding, Beginning balance
Number of shares, Options granted
Number of shares, Options exercised
Number of shares, Options cancelled/forfeit
Number of shares, Outstanding, Ending balance
Number of shares, Options exercisable
Number of shares, Options vested and expected to vest
Weighted Avg. Exercise Price, Outstanding, Beginning balance
Weighted Avg. Exercise Price, Options granted
Weighted Avg. Exercise Price, Options exercised
Weighted Avg. Exercise Price, Options cancelled/forfeit
Weighted Avg. Exercise Price, Outstanding, Ending balance
Weighted Avg. Exercise Price, Exercisable Ending Balance
Weighted Avg. Exercise Price, Vested and expected to vest
Weighted Avg. Remaining Contractual Life, Options outstanding
Weighted Avg. Remaining Contractual Life, Options exercisable
Weighted Avg. Remaining Contractual Life, Options vested and expected to vest
Aggregate Intrinsic Value, Options outstanding
Aggregate Intrinsic Value, Options exercisable
Aggregate Intrinsic Value, Options vested and expected to vest
Weighted-average fair value of options granted
Expected terms (in years)
Expected volatility, minimum
Expected volatility
Expected volatility, maximum
Risk-free interest rate, minimum
Risk-free interest rate
Risk-free interest rate, maximum
Dividend yield
Range of Exercise Prices, minimum
Range of Exercise Prices, maximum
Number of Options Outstanding
Weighted Average Remaining Contractual Life in Years
Weighted Average Exercise Price
Number Exercisable
Weighted Average Exercisable Exercise Price
Number of RSUs unvested, Outstanding, Beginning balance
Number of RSUs granted
Number of RSUs vested
Number RSUs cancelled/forfeit
Number of RSUs unvested, Outstanding, Ending balance
Weighted Average Grant Date Fair Value, Beginning balance
Weighted Average Grant Date Fair Value, RSUs granted
Weighted Average Grant Date Fair Value, RSUs vested
Weighted Average Grant Date Fair Value, Ending balance
Stock based compensation related to equity instruments granted to related parties
Number of Shares Subject to Warrants, Outstanding, beginning balance
Number of Shares Subject to Warrants Outstanding, Granted
Number of Shares Subject to Warrants Outstanding, Exercised
Number of Shares Subject to Warrants Outstanding, Expired
Number of Shares Subject to Warrants, Outstanding, ending balance
Weighted average remaining contractual life of the outstanding warrants in years
Weighted avg. Exercise Price, outstanding, beginning balance
Weighted avg. Exercise Price, exercised
Weighted avg. Exercise Price, expired
Weighted avg. Exercise Price, outstanding and exercisable, ending balance
Issue Date
Warrants Outstanding
Exercise Price
Warrants Exercisable
Expiration Date
Deferred tax asset valuation allowance
Federal net operating loss carryforwards
Federal research and development tax credits expiration date
Federal research and development tax credits
State net operating loss carryforwards
State net operating loss expiration date
State research and development tax credits
Corporate tax rate, percentage
Current: Federal
Current: State
Total current
Deferred: Federal
Deferred: State
Deferred: Change in valuation allowance
Total deferred
Income tax provision (benefit)
U.S. federal statutory tax rate
Benefit of lower tax brackets
State tax benefit, net
Research and development credits
Employee stock based compensation
Loss on debt conversion
Change in Rate
Other
Valuation allowance
Effective income tax rate
NOL's
Depreciation and amortization
Other
Research & development credits
Deferred stock compensation
Basis Difference in Surface
Basis Difference in Eton
Park stock purchase identifiable intangibles
Total deferred tax assets, net
Valuation allowance
Net deferred tax liabilities
UTB, Beginning balance
Additions for tax positions related to current year
Additions/(reductions) for tax positions related to prior years
UTB, Ending balance
Percentage of salary deposits in tax deferred investment account
Percentage of contributions made by the company
Contributions by the company
Lease agreement for office space (square feet)
Operating lease, monthly rental
Operating lease, rent increase percentage
Operating lease expiry
Operating lease expiration, description
Damages in lawsuit
Accrued expenses
Royalty payments
Net sales
Commission payments, percentage
Stock based payments
Commission expense incurred
Accounts payable and accrued expenses
Incurred royalty expenses
2019
2020
2021
2022
2023
2024
Total
Number of reportable segment
Maximum percentage of sales derived from large number of customer
Percentage of drug and chemical purchases from three main suppliers
Common stock issued exercise price per share
Net proceeds from issuance of common stock
Number of warrants exercised
Payment to asset purchase
Royalty percentage
Payments for Royalty
Gross proceeds from royalty
Gross profit
Segment contribution
Corporate
Amortization
Asset sales and impairments, net
Operating loss
Andrew R Boll [Member]
Cantor Fitzgerald & Co [Member]
Cash and cash equivalents and Restricted cash at end of period.
Cash commission, percentage.
Closing price of common stock price per share.
Consultant
Consultants Employees and Directors [Member]
Deferred Acquisition Obligation and Accrued Interest Current.
Deferred Acquisition Obligations, Convertible Note Payable, Stock Options, Unvested RSUs and Warrants [Member]
Employees [Member]
Eton Pharmaceuticals, Inc. [Member]
Final Payment [Member]
Finite Lived Intangible Assets Impairment.
Forfeiture factor, percentage.
Initial Payment [Member]
John P Saharek [Member]
Klarity License Agreement [Member]
Lender Warrants [Member]
Lender Warrants One [Member]
License Revenue [Member]
Licenses [Member]
Liquidity Disclosure [Policy Text Block]
Note Payable [Member]
Options granted to employees
Placement Agent Warrants [Member]
Product Sales, Net [Member]
Range five [member]
Range four [member].
Range one [member].
Range three [member].
Range two [member].
Recently Adopted Accounting Pronouncements [Policy Text Block]
Reconciliation of Cash and cash equivalents.
Reconciliation Restricted cash.
Richard L. Lindstrom, M.D [Member]
Royalty payment description.
Sales Agreement [Member]
Sales and Marketing Agreements [Member]
Sales commission and offering expenses.
Schedule Of Prepaid Expenses and Other Current Assets [Table Text Block].
Schedule of warrants outstanding and exercisable [Table Text Block]
Second Payment [Member]
Selling, General and Administrative [Member]
Settlement Warrants [Member]
Share based compensation arrangement by share based payment award non options outstanding weighted average exercise price.
Share based compensation arrangements by share based payment award non options expirations in period weighted average exercise price.
Warrants exercisable.
Sharebased compensation arrangement by sharebased payment award non options exercisable weighted average remaining contractual term.
State Pharmacy Licenses [Member]
StockOptionPlanMember
Stock Options [Member]
2007 Incentive Stock and Awards Plan [Member]
unvested RSUs [Member]
Warrants expiration date.
Warrants issuance date.
Warrants Issued To Investor Relations Consultant One [Member]
Surface Pharmaceuticals [Member]
Eton Pharmaceuticals [Member]
Investments And Agreements - Related Party Transactions [Text Block]
Employees and Consultants [Member]
Surface Series A Stock [Member]
Surface Pharmaceuticals Inc [Member]
Surface License Agreements [Member]
Management Services Agreement [Member]
Dr. Lindstrom [Member]
Payments of license.
Final fee on note payable recorded as debt discount and Included in accrued expenses.
Estimated relative fair value of warrants issued in connection with note payable.
Note receivable in connection with sale of assets.
Share based compensation arrangements by share based payment award non options exercised in period weighted average exercise price.
Common Stock Warrant One [Member]
2017 Incentive Stock and Awards Plan [Member]
Number of warrants exercised.
Common Stock Warrants [Member]
Stock issued during period for exercise of warrants.
Stock issued during period shares for exercise of warrants.
Vesting of restricted stock unit net of tax withholding.
Vesting of restricted stock unit net of tax withholding shares.
Asset Sales and Note Receivable [Text Block]
Third party billing and collection agreements [Policy Text Block]
Eton Pharmaceuticals, Inc. One [Member]
Eton Pharmaceuticals, Inc. Two [Member]
Surface Pharmaceuticals Inc One [Member]
Surface Pharmaceuticals Inc Two [Member]
Percentage of billing and collection amount.
Billing and collection management expense.
Billing and Collection Agreement [Member]
Third Party [Member]
Eton License Agreements [Member]
Management Services Agreement [Member]
Royalty payment percentage on net sales.
Royalty payment percentage on net sales patent claims not issued.
Payment on issuances of patent.
Amount paid for services.
Asset Purchase Agreement [Member]
Pharmacy Solutions Central, LLC [Member]
December 31, 2017 [Member]
Stock Purchase Agreement [Member]
Livernois [Member]
Imprimis TX [Member]
Payment to closing cash amount.
Disposal Group, Including Discontinued Operation, Assets, Loss on Assets for sale.
Loan and Security Agreement [Member]
Life Sciences Alternative Funding LLC [Member]
Loan Agreement [Member]
Note Purchase Agreement [Member]
8.00% Convertible Senior Secured Note [Member]
Convertible Note [Member]
Exchange Agreement [Member]
SWK Loan Agreement [Member]
LSAF Loan [Member]
London Inter-Bank Offered Rate [Member]
SWK Warrants [Member]
Percentage of loan agreement final fee.
Percentage of loan agreement prepayment fee.
Warrant term.
Fair value assumptions, measurement input, percentages.
Fair value assumptions, measurement input, term.
Fair value assumptions, measurement input, per share.
Notes Payable [Member]
Lease Agreement [Member]
Lease monthly payments.
Lease future payment.
Cost of sales [Policy Text Block]
Federal Research And Development Tax Credits Expiration Date.
Federal Research And Development Tax Credits.
State net operating loss expiration date.
State Research And Development Tax Credits.
Deferred Income Change In Valuation Allowance.
Effecticve Income Tax Rate Benefit Of Lower Tax Brackets.
Effective Income Tax Rate Loss On Debt Conversion.
Deferred Tax Asset Tax Credit carry Forwards Depreciation And Amortization.
Basis Difference in Surface.
Basis Difference in Eton.
Percentage of salary deposits in tax deferred investment account.
Amended Lease Agreement [Member]
Commercial Lease Agreement [Member]
February 2019 [Member]
License Agreement [Member]
Commission payments, percentage.
Incurred royalty expenses.
Settlement Agreement [Member]
Percentage of drug and chemical purchases from three main suppliers.
Cashless Warrants Exercise [Member]
May Asset Purchase Agreement [Member]
Elle Pharmaceutical, LLC [Member]
Elle Royalty Agreement [Member]
Mayfield Pharmaceutical, LLC [Member]
May Asset Purchase And Elle Royalty Agreement [Member]
Royalty percentage.
Gross proceeds from royalty.
Pharmaceutical Compounding [Member]
Pharmaceutical Drug Development [Member]
Segment contribution.
Amended and Restated Certificate of Incorporation [Member]
Net proceeds of registered offering.
Gross proceeds, percentage.
Securities Purchase Agreements [Member]
Two Accredited Investors [Member]
Number of common stock issued for warrant exercises.
Range Six [Member]
Selling And Marketing [Member]
General And Administrative [Member]
Other [Member]
PIPE Investor and Placement Agent Warrants [Member]
Disclosure of accounting policy for investments in financial assets, including marketable securities (debt and equity securities with readily determinable fair values), investments accounted for under the equity method and cost method, securities borrowed and loaned, and repurchase and resale agreements. For marketable securities, the disclosure may include the entity's accounting treatment for transfers between investment categories and how the fair values for such securities are determined. Also, for all investments, an entity may describe its policy for assessing, recognizing and measuring impairment of the investment.
Schedule of Assets Sales and Note Receivable [Table Text Block]
Incremental Common Shares Attributable to Dilutive common equivalents.
Previously Authorized Shares [Member]
Non Employee Directors [Member]
Stock Option Plan [Member]
Tax Reform [Member]
Corporate.
ManagementServicesAgreementMember
StockOptionPlanOneMember
Assets, Current
Liabilities, Current
Cost of Goods and Services Sold
Operating Expenses
Nonoperating Income (Expense)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Income Tax Expense (Benefit)
Income (Loss) from Equity Method Investments
Issuance of Stock and Warrants for Services or Claims
Increase (Decrease) in Accounts Receivable
Increase (Decrease) in Inventories
Increase (Decrease) in Prepaid Expense and Other Assets
Increase (Decrease) in Accounts Payable and Accrued Liabilities
Increase (Decrease) in Employee Related Liabilities
Increase (Decrease) in Contract with Customer, Liability
Payments to Acquire Intangible Assets
PaymentsOfLicense
Net Cash Provided by (Used in) Investing Activities
Repayments of Debt and Capital Lease Obligations
Payments of Financing Costs
Repayments of Notes Payable
Net Cash Provided by (Used in) Financing Activities
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect
ReconciliationRestrictedCash
StockOption5Member
Inventory Disclosure [Text Block]
Income Tax, Policy [Policy Text Block]
Inventory, Policy [Policy Text Block]
Property, Plant and Equipment, Policy [Policy Text Block]
Disposal Group, Including Discontinued Operation, Inventory, Current
Disposal Group, Including Discontinued Operation, Assets, Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationLossOnAssetSale
Assets Held-for-sale, Not Part of Disposal Group, Current
Furniture and Fixtures, Gross
Property, Plant and Equipment, Gross
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Finite-Lived Intangible Assets, Accumulated Amortization
Finite-Lived Intangible Assets, Net
Accounts Payable and Accrued Liabilities
Debt Instrument, Unamortized Discount
Long-term Debt, Maturities, Repayments of Principal in Next Twelve Months
Long-term Debt, Maturities, Repayments of Principal in Year Two
Long-term Debt, Maturities, Repayments of Principal in Year Three
Long-term Debt, Maturities, Repayments of Principal in Year Four
Interest Payable, Current
Capital Leases, Future Minimum Payments Due, Next Twelve Months
Capital Leases, Future Minimum Payments Due
Capital Leases, Future Minimum Payments, Interest Included in Payments
Capital Leases, Future Minimum Payments, Net Minimum Payments
Capital Leases, Future Minimum Payments, Present Value of Net Minimum Payments
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingWeightedAverageExercisePrice1
Current Income Tax Expense (Benefit)
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent
Deferred Tax Assets, Tax Credit Carryforwards, Other
Deferred Tax Assets, Tax Credit Carryforwards, General Business
Deferred Tax Assets, Net of Valuation Allowance
Deferred Tax Assets, Valuation Allowance
Deferred Tax Assets, Net
Unrecognized Tax Benefits
Accounts Payable and Other Accrued Liabilities
Operating Leases, Future Minimum Payments, Next Rolling Twelve Months
Operating Leases, Future Minimum Payments, Due in Rolling Year Two
Operating Leases, Future Minimum Payments, Due in Rolling Year Three
Operating Leases, Future Minimum Payments, Due in Rolling Year Four
Operating Leases, Future Minimum Payments Due